Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer
暂无分享,去创建一个
Pauline M. Rudd | Denis C. Shields | John O'Leary | Susie Boyce | Sarah Gilgunn | Keefe Murphy | Brendan T. Murphy | Louise Flynn | Colm J. O'Rourke | Cathy Rooney | Henning Stöckmann | Anna L. Walsh | Stephen Finn | Richard J. O'Kennedy | Stephen R. Pennington | Antoinette S. Perry | Radka Saldova | Orla Sheils | R. William Watson | S. Pennington | D. Shields | O. Sheils | P. Rudd | R. Watson | K. Murphy | S. Finn | S. Gilgunn | R. Saldova | C. O’Rourke | H. Stöckmann | A. Perry | J. O'Leary | L. Flynn | C. Rooney | B. Murphy | Susie Boyce | R. O’Kennedy | Keefe Murphy | A. Perry
[1] P. Tan,et al. Diagnostic and Prognostic Utility of a DNA Hypermethylated Gene Signature in Prostate Cancer , 2014, PloS one.
[2] Jouhyun Jeon,et al. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer , 2016, Nature Communications.
[3] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..
[4] Benjamin R Saville,et al. Decision curve analysis. , 2015, JAMA.
[5] L. Holmberg,et al. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study , 2011, Cancer Causes & Control.
[6] D. Stein,et al. Evaluation of matrix effect and chromatography efficiency: new parameters for validation of method development , 2005, Journal of the American Society for Mass Spectrometry.
[7] Ruedi Aebersold,et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[8] Thomas Brendan Murphy,et al. Evaluation of prediction models for the staging of prostate cancer , 2013, BMC Medical Informatics and Decision Making.
[9] Ludmila I. Kuncheva,et al. Combining Label Outputs , 2014 .
[10] Tong Li,et al. miR‐20a Promotes Prostate Cancer Invasion and Migration Through Targeting ABL2 , 2014, Journal of cellular biochemistry.
[11] W. Gallagher,et al. Commercialized biomarkers: new horizons in prostate cancer diagnostics , 2015, Expert review of molecular diagnostics.
[12] A. Albert,et al. On the existence of maximum likelihood estimates in logistic regression models , 1984 .
[13] Madhusudana Shashanka,et al. Linear Methods for Regression , 2009 .
[14] Igor Jurisica,et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.
[15] J. A. Ferreira,et al. Approximate Sample Size Calculations with Microarray Data: An Illustration , 2006, Statistical applications in genetics and molecular biology.
[16] Yuanyuan Liang,et al. Updating risk prediction tools: A case study in prostate cancer , 2012, Biometrical journal. Biometrische Zeitschrift.
[17] John Aitchison,et al. The Statistical Analysis of Compositional Data , 1986 .
[18] Yvonne Vergouwe,et al. Discrimination ability of prediction models for ordinal outcomes: Relationships between existing measures and a new measure , 2012, Biometrical journal. Biometrische Zeitschrift.
[19] S. Hewitt,et al. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer , 2013, International journal of cancer.
[20] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[21] E. Elkin,et al. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[22] M. Cooperberg,et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Anton K. Formann. Mixture analysis of multivariate categorical data with covariates and missing entries , 2007, Comput. Stat. Data Anal..
[24] Anthony D'Amico,et al. Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[25] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[26] David L Rimm,et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer , 2015, Clinical Cancer Research.
[27] M. Mann,et al. Universal sample preparation method for proteome analysis , 2009, Nature Methods.
[28] R. William G. Watson,et al. Biomarker research in prostate cancer—towards utility, not futility , 2011, Nature Reviews Urology.
[29] Thomas Brendan Murphy,et al. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. , 2011, Journal of proteome research.
[30] M. Schemper,et al. A solution to the problem of separation in logistic regression , 2002, Statistics in medicine.
[31] C. Creighton,et al. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer , 2016, Nature Communications.
[32] A. D'Amico,et al. NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[33] M. Babjuk,et al. Importance of miR-20a expression in prostate cancer tissue. , 2010, Anticancer research.
[34] M. Loda,et al. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer , 2015, Clinical Cancer Research.
[35] T. Golub,et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] C. Eyers. Universal sample preparation method for proteome analysis , 2009 .
[37] Ludmila I. Kuncheva. Fusion of Label Outputs , 2004 .
[38] Pauline M Rudd,et al. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. , 2006, Methods in molecular biology.
[39] S. Serrano,et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression. , 2012, The American journal of pathology.
[40] David J. Harvey,et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. , 2008, Analytical biochemistry.
[41] D. McMillan,et al. Systemic Inflammatory Response and Survival in Patients with Localised Prostate Cancer: 10-Year Follow-Up , 2010, Urologia Internationalis.
[42] S. Klauck,et al. Novel RNA Markers in Prostate Cancer: Functional Considerations and Clinical Translation , 2014, BioMed research international.
[43] Yue Fan,et al. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. , 2011, Glycobiology.
[44] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[45] Colin Campbell,et al. A pathway-based data integration framework for prediction of disease progression , 2013, Bioinform..